Illumina (ILMN) reported fourth-quarter revenue of $928 million, exceeding estimates by 6.3%, driven by robust demand in genomic sequencing and diagnostic solutions. The stock surged 8.4% in after-hours trading, boosting related healthcare ETFs like XLV and IHH.
- Illumina reported Q4 revenue of $928 million, 6.3% above estimates
- Adjusted EPS of $1.16 beat forecasts by 7.4%
- Diagnostic product sales up 19% YoY
- Full-year 2026 revenue guidance raised to $3.85B–$3.95B
- ILMN shares rose 8.4% in after-hours trading
- XLV and IHH ETFs gained 1.6% and 2.1% respectively
Illumina (ILMN) delivered a standout performance in its latest fiscal quarter, reporting revenue of $928 million, surpassing analyst expectations by $58 million. The company's adjusted earnings per share reached $1.16, outpacing the consensus forecast of $1.08 by 7.4%. This beat was primarily fueled by strong adoption of its NovaSeq X and NextSeq platforms, particularly in clinical diagnostics and research applications across North America and Europe. The results underscore sustained demand in the genomics sector, with Illumina's sequencing systems contributing 62% of total revenue, up from 58% in the prior year. Diagnostic product sales rose 19% year-over-year, signaling growing integration of genetic testing into routine healthcare workflows. The company also raised its full-year 2026 revenue guidance to a range of $3.85 billion to $3.95 billion, up from $3.7 billion previously. Market reaction was immediate: ILMN shares climbed 8.4% in after-hours trading, marking one of the strongest single-day gains in the biotechnology sector this quarter. The rally extended to broader healthcare indices, with the Health Care Select Sector SPDR Fund (XLV) rising 1.6% and the iShares Health Care Innovators ETF (IHH) gaining 2.1%. Analysts noted that Illumina’s performance reflects a structural shift toward precision medicine, reinforcing investor confidence in genomics-driven healthcare innovation.